PU535 Unit 5 Chronic Disease Pathway Paper Example

An Infection at Six, a Diagnosis at Sixty-One: A Chronic Disease Pathway Paper Following Helicobacter pylori Through Forty Years of Quiet Stomach Inflammation to Gastric Cancer, and Asking Where in That Span Public Health Can Still Act

[Student Name]

Purdue University Global

PU535: Public Health Biology - A Global Perspective

Unit 5 Chronic Disease Pathway Paper

[Instructor Name]

[Date]

The family and the district are composite; the stages, the risk figures and the research cited are real.

Two Dates, Forty-Five Years Apart

A composite man born in a crowded household in 1965 acquired Helicobacter pylori before he started school, which is when most infections are acquired and when they are almost never noticed. He had episodes of indigestion in his thirties that nobody tested. In 2026, at 61, he was diagnosed with gastric cancer after months of vague fullness and a falling blood count. Nothing dramatic happened in between. That is the difficulty this pathway presents to public health: the exposure and the outcome are separated by a span longer than most programs, budgets or careers.

Stage One: Acquisition in Childhood

Transmission is person to person within households, and the usual age of acquisition is early childhood. Infection remains common worldwide, with more than half the global population carrying the organism, and prevalence falls as household crowding and shared sleeping space decline (Hooi et al., 2017). Two features of this stage matter for the rest of the pathway. First, the infection usually persists for life unless it is treated, so an exposure at six is an exposure that continues at sixty. Second, nothing about the first stage identifies the few who will reach the last one.

Stage Two: Chronic Inflammation, Decades Long

The infected stomach lining mounts a persistent inflammatory response that does not clear the organism. For most people that is the end of the story; they carry the infection and the inflammation and never develop a tumor. In a minority, the inflammation extends over decades into loss of the normal acid-producing glands, then into a lining that comes to resemble intestinal tissue rather than stomach, and in a smaller group still into changes a pathologist grades as dysplasia. Each step takes years, and progression is not inevitable at any of them. This stepwise sequence from inflammation through glandular loss and metaplasia to carcinoma is the model this course works from, proposed from pathology and population data four decades ago and still the framework for screening programs (Correa & Piazuelo, 2012). The forty-year latency that makes this pathway hard to study is the same forty years that make it possible to interrupt.

Stage Three: Who Progresses and Why

Three groups of factors separate the man in this case from the many people who carry the same infection and stay well. The bacterial strain matters, since strains differ in the proteins that drive inflammation. The host matters, through inherited differences in inflammatory response and through family history; among people with a family history of gastric cancer, risk is high enough that treating the infection measurably lowers it (Choi et al., 2020). Diet and smoking matter: heavily salted and preserved foods, which this composite household ate through the 1970s because they had no refrigerator, raise risk alongside the infection rather than instead of it. The cohort evidence that anchors the whole pathway comes from following infected and uninfected people for years and finding cancers almost entirely among the infected, with none in the uninfected group (Uemura et al., 2001).

How the Stages Were Established

A pathway this slow cannot be demonstrated by watching one person, and the paper says so rather than implying that the case proves anything. Three kinds of study built it. Pathologists compared stomach biopsies across age groups in high-incidence and low-incidence populations and found the same stages in the same order, arriving earlier where cancer was common. Cohort studies followed infected and uninfected adults for a decade or more and compared who developed cancer. Trials treated the infection in one group and not in another and counted cancers years later. Each design answers a different question, and only the third can show that acting on the pathway changes the outcome. The composite man in this paper illustrates the stages; he does not establish them, and a pathway paper that confuses illustration with evidence loses the argument it is making.

Stage Four: The Diagnosis, and Why It Came Late

Early gastric cancer causes little, and what it causes is indigestion, which middle-aged adults and their clinicians treat with acid suppression. Acid suppression relieves the symptom without touching the cause, so the consultation that could have led to testing ends in a prescription. By the time fullness, weight loss or anemia appear, the tumor has usually grown through the stomach wall. The man's diagnosis at a late stage was therefore not bad luck; it was the predictable result of a pathway whose only early sign is a symptom that has a cheap, effective and entirely unrelated treatment. The district's own records show the shape of this problem: among adults given acid-suppressing drugs for more than six months, almost none had been tested for the infection, and the median age at that first prescription was forty-four, seventeen years before this man's diagnosis. Seventeen years is a long time to hold a fact that nobody wrote down.

Where the Pathway Can Be Broken

At stage one, the exposure can be prevented. Household crowding and shared bedding fell across high-income countries through the twentieth century, and infection in children fell with them, which is most of the reason gastric cancer rates in those countries dropped without anyone aiming at the disease. At stage two, the infection can be treated. Antibiotic treatment of infected adults lowers later gastric cancer incidence, with the clearest benefit in populations where the disease is common (Ford et al., 2020). At stage three, the precancerous lining can be found and watched, which is what endoscopic screening programs in high-incidence countries do. At stage four, only treatment remains, and it is expensive and often unsuccessful. The order of these options follows the pathway, and the earliest is the cheapest.

What the Pathway Argues for in This District

The district in this case has a middling incidence, no screening program and no infection testing outside of symptomatic care. The paper recommends two things that fit its means. Test and treat the infection in adults who have a parent or sibling with gastric cancer, since that group's risk and benefit are both the largest. Second, record infection status when an adult is treated for persistent indigestion, so that the consultation at forty leaves behind a fact rather than only a prescription. A broader screening program is not recommended here, because the burden that would justify it is not present. The wider claim stands regardless: roughly one in six cancers worldwide is attributable to infection, and this organism accounts for the largest single share of them (Plummer et al., 2016). A pathway with a forty-year latency is slow enough to be interrupted, and that is the argument of the paper.

References

Choi, I. J., Kim, C. G., Lee, J. Y., Kim, Y. I., Kook, M. C., Park, B., & Joo, J. (2020). Family history of gastric cancer and Helicobacter pylori treatment. The New England Journal of Medicine, 382(5), 427-436. https://doi.org/10.1056/NEJMoa1909666

Correa, P., & Piazuelo, M. B. (2012). The gastric precancerous cascade. Journal of Digestive Diseases, 13(1), 2-9. https://doi.org/10.1111/j.1751-2980.2011.00550.x

Ford, A. C., Yuan, Y., & Moayyedi, P. (2020). Helicobacter pylori eradication therapy to prevent gastric cancer: Systematic review and meta-analysis. Gut, 69(12), 2113-2121. https://doi.org/10.1136/gutjnl-2020-320839

Hooi, J. K. Y., Lai, W. Y., Ng, W. K., Suen, M. M. Y., Underwood, F. E., Tanyingoh, D., Malfertheiner, P., Graham, D. Y., Wong, V. W. S., Wu, J. C. Y., Chan, F. K. L., Sung, J. J. Y., Kaplan, G. G., & Ng, S. C. (2017). Global prevalence of Helicobacter pylori infection: Systematic review and meta-analysis. Gastroenterology, 153(2), 420-429. https://doi.org/10.1053/j.gastro.2017.04.022

Plummer, M., de Martel, C., Vignat, J., Ferlay, J., Bray, F., & Franceschi, S. (2016). Global burden of cancers attributable to infections in 2012: A synthetic analysis. The Lancet Global Health, 4(9), e609-e616. https://doi.org/10.1016/S2214-109X(16)30143-7

Uemura, N., Okamoto, S., Yamamoto, S., Matsumura, N., Yamaguchi, S., Yamakido, M., Taniyama, K., Sasaki, N., & Schlemper, R. J. (2001). Helicobacter pylori infection and the development of gastric cancer. The New England Journal of Medicine, 345(11), 784-789. https://doi.org/10.1056/NEJMoa001999